Lumibird SA

Lumibird SA

23.10
EUR
-0.10
(-0.43%)
564.97MMarket Cap
Mar 16Next Earn
Lumibird SA
EURONEXT:LBIRD
(Euronext)

Recent

price

23.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
EUR
13.09
12.11
11.98
7.62
6.51
7.77
1.95
2.39
6.43
6.64
5.77
7.41
8.73
9.35
9.54
10.38
- -
Revenue per Share
0.17
0.29
-0.83
-0.05
-0.14
0.26
0.24
0.11
0.51
0.52
0.25
0.62
0.51
0.32
0.26
0.64
- -
Basic EPS, GAAP
0.25
-0.68
-1.15
-0.27
-0.36
0.54
0.22
0.21
0.07
0.48
0.03
0.29
-1.26
-0.22
0.52
0.57
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
0.58
0.07
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
4.62
4.66
3.85
2.64
2.88
3.33
1.01
4.7
5.42
6.78
7.39
8.17
8.68
8.75
9
9.37
9.43
Book Value per Share
0.89
1.14
1.54
1.19
1.37
1.65
0.51
1.49
2.19
3.11
2.47
2.87
3.14
2.82
2.54
3.1
9.43
Tangible Book Value per Share
4
4
4
7
8
8
9
16
16
17
22
22
22
22
22
22
22
Basic Weighted Avg Shares
56
51
50
55
53
63
17
38
102
113
130
166
194
207
210
229
- -
Sales/Revenue/Turnover
1.8
6.75
6.66
2.28
-0.59
3.67
17.58
8.94
11.18
10.85
7.83
11.81
8.4
8.91
7.1
11.22
- -
Operating Margin (%)
4
3
3
3
3
3
1
3
5
9
10
12
15
16
18
19
- -
Depreciation Expense
1
1
-3
- -
-1
2
2
2
8
9
6
14
11
7
6
14
- -
Net Income, GAAP
- -
- -
- -
49.43
- -
- -
30.33
26.81
26.04
16.59
21.6
21.28
21.36
4.39
12.78
26.09
- -
Effective Tax Rate (%)
1.31
2.39
-6.92
-0.61
-2.09
3.36
12.32
4.6
7.93
7.83
4.35
8.33
5.84
3.45
2.71
6.13
- -
Profit Margin (%)
11
11
11
10
9
10
7
25
42
69
105
125
67
123
129
129
73
Working Capital
- -
14
5
5
5
4
5
13
17
25
72
98
49
129
142
124
128
LT Debt
18
20
16
19
23
27
9
75
91
125
164
181
193
193
198
206
208
Total Equity
- -
- -
- -
1.95
- -
- -
7.61
3.62
7.8
6.82
3.27
5.43
4.44
3.53
2.83
4.86
- -
Return on Invested Capital (%)
- -
- -
- -
0.24
- -
- -
7.86
3.58
8
6.92
3.29
5.73
4.65
3.45
3.2
5.12
- -
Return on Capital (%)
4.18
6.38
-19.31
-1.92
-5.19
8.42
11.8
4.17
9.77
8.18
3.9
8.02
6.06
3.69
2.91
6.93
- -
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
21
22
- -
LT Borrowings
136
117
128
LT Finance Leases
9
8
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
22
22
22
Market Capitalization
407
467
565

Working Capital

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
222
217
161
Cash, Cash Equivalents & STI
126
62
58
Accounts Receivable, Net
- -
61
- -
Inventories
83
82
- -
Total Current Liabilities
85
88
88
Payables & Accruals
- -
- -
- -
ST Debt
21
22
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
78.24%
4.75%
4.19%
Free Cash Flow
34.97%
-34.44%
10.85%
Net Income, GAAP
53.54%
43.28%
145.97%
Sales/Revenue/Turnover
30.34%
12.41%
8.79%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
210
2025
- -
- -
229
2026
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.26
2025
- -
- -
0.64
2026
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Business
Lumibird SA designs, manufactures and markets high-performance lasers and associated technologies for scientific, industrial, medical and defense applications worldwide. The company operates through two main divisions, Photonics and Medical, with the Photonics division encompassing brands including Quantel, Keopsys, Convergent, SensUp and Halo Photonics; core products comprise solid-state lasers such as Q-switched Nd:YAG lasers at wavelengths including 1064 nm, 532 nm, 355 nm and 266 nm with energies from 5 mJ to 2.3 J, fiber lasers and amplifiers including high-power CW and QCW models, Raman fiber lasers up to 20 W at 1455 nm and 1480 nm, single-frequency CW fiber lasers with linewidths down to 1 kHz at 1054 nm, 1083 nm and 1.5 µm, laser diodes and modules including QCW stacks and fiber-coupled variants, tunable dye lasers from 200 nm to 4.5 µm, frequency-converted yellow and orange lasers from 520 nm to 590 nm, and LIDAR sensors; the Medical division provides ophthalmic diagnostic and treatment equipment including photocoagulation lasers, YAG lasers, SLT lasers, ultrasound devices such as UBM, subthreshold lasers and dry eye solutions. Founded in 2017 through the merger of Keopsys and Quantel with over 50 years of combined expertise and headquartered in Lannion, France, Lumibird maintains 12 production and R&D sites across Europe and North America, eight international subsidiaries, representative offices in Brazil and Thailand, and a distributor network spanning 110 countries targeting research laboratories, universities, manufacturing, defense, LiDAR applications and ophthalmology professionals. Recent developments include the 2023 acquisition of Convergent Photonics from Prima Industrie enhancing high-power fiber lasers and semiconductor capabilities, the October 2024 agreement to acquire the Continuum nanosecond laser product line and services from Amplitude Laser Group adding over €7m in annual sales and bolstering North American scientific market leadership, a June 2025 major naval contract for VIDAR laser rangefinders awarded to Lumibird Photonics Sweden with Saab and DALO, laser rangefinder orders for the Skyranger 30 system, and October 2024 bank financing renewal exceeding €100m supporting strategic growth with Q3 2024 revenue growth and targets of over 5% sales increase and 16% EBITDA margin.